One year later, the baby formula shortage continues to plague families across the country, and relief from the Biden administration is seemingly nowhere in sight.
FOX Business Lydia Hu spoke with pharmacy owner Anil Datwani, who issued a warning to parents that demand for formula is growing while supply is dwindling.
It's getting harder and harder, according to the AR-Ex pharmacy owner, adding that it's a struggle to find Enfamil A.R. Mothers go from one store to the next store to the next store looking for these formulas, he explained.
The Biden administration has been saying that they are working around the clock to deal with the issue, but the shortage continues to burden American mothers in March 2023, despite the fact that the baby formula shortage began in February 2022.
In an effort to take constructive action, House Republicans opened an investigation into the Food and Drug Administration's poor response to Tuesday.
The House Oversight Committee wants to talk to former FDA official Frank Yiannas, who was responsible for the baby formula crisis during its initial eruption last year. Yiannas shocked many when he resigned from the FDA earlier this year.
Chairman of the House Oversight Committee James Comer, R-Ky., sent a letter to FDA Commissioner Robert Califf asking for all the administration's communications relating to the shortage and its response. In January, Califf said that the FDA wouldn't fire anyone over its response to the crisis.
Comer's letter is referring to a review of the FDA's response by a third party, which found that the organization lacked urgency and motivation in responding to the shortage.
Comer wrote in the letter that there would be no reassignments or firings over the administration's response to the infant formula shortage despite the report and the acknowledged need for a major overhaul. The FTC and SEC have launched their own investigations into the maker of popular formula brand Similac, Abbott Laboratories, along with the Department of Justice's in-progress criminal investigation.
Numerous lawsuits are being filed against Abbott Laboratories.